Combined PET–CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy
- 19 May 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 104 (9), 1188-1196
- https://doi.org/10.1002/bjs.10555
Abstract
Background The treatment of axillary lymph node metastases after neoadjuvant systemic therapy (NST) remains debatable and axillary lymph node dissection (ALND) is still the standard of care. Marking axillary lymph nodes with radioactive iodine seeds (MARI procedure) is accurate in restaging the axilla after NST (false-negative rate 7 per cent). Here, the potential of tailored axillary treatment, determined by combining the results of PET–CT before NST with those of the MARI procedure after NST, was analysed. Methods A cohort of axillary node-positive patients was used to construct a hypothetical treatment algorithm based on a combination of PET–CT and the MARI procedure. In the algorithm, the number of fluorodeoxyglucose (FDG)-avid axillary lymph nodes (1–3 versus 4 or more) before NST and the tumour status of the MARI node (positive versus negative) after NST were used to tailor axillary treatment. All patients in the cohort underwent ALND, allowing estimation of potential overtreatment and undertreatment. Results A total of 93 patients were included in the study. Between one and three FDG-avid axillary lymph nodes were observed in 59 patients, and four or more in 34 patients. The MARI node was tumour-negative in 32 patients and showed residual disease in 61. Treatment according to the constructed algorithm would have resulted in 74 per cent of patients avoiding an ALND, with potential undertreatment in three patients (3 per cent) and overtreatment in 16 (17 per cent). Conclusion Tailored axillary treatment after NST in node-positive patients, by combining PET–CT before NST and the MARI procedure after NST, has the potential for ALND to be avoided in 74 per cent of patients.Keywords
This publication has 41 references indexed in Scilit:
- Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysisBMC Cancer, 2015
- Role of Imaging in Neoadjuvant Therapy for Breast CancerAnnals of Surgical Oncology, 2015
- Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast CancerAnnals of Surgery, 2014
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Use of Sentinel Lymph Node Biopsy to Select Patients for Local–Regional Therapy After Neoadjuvant ChemotherapyCurrent Breast Cancer Reports, 2014
- Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patientsEuropean Journal of Cancer, 2011
- Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancerCancer, 2010
- Breast Cancer: Sentinel Node Identification and Classification after Neoadjuvant Chemotherapy—Systematic Review and Meta AnalysisAcademic Radiology, 2009
- Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literatureEuropean Journal of Surgical Oncology, 2008
- Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-AnalysisJNCI Journal of the National Cancer Institute, 2005